Close Window

Digital Look Email A Friend

Bioventix full-year revenue and profits improve

Published by Josh White on 21st October 2019

(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to 9.3m.


Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.